Please assess the completion status of the following clinical trial:

Trial Title: Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Child healthy (stable chronic conditions acceptable) as established by health assessment interview and verbal history-directed health examination~* Child between and including 6 months of age and 23 months of age (up to and including the day before 24 months of age)~* Child is available and can complete all relevant procedures during the entire study period~* Parent or legal guardian is available and can be reached by phone during the entire study period~* Parent/guardian provides written informed consent~* Parent/guardian is fluent in English~Exclusion Criteria:~* Child has history of laboratory-confirmed influenza~* Child has history of any prior influenza immunization~* Child has history of anaphylactic reaction to any component of the vaccine (i.e. egg)~* Child has received immune globulin or other blood products within the prior six weeks~* Child has received injected or oral steroids within the prior six weeks (inhaled or topical steroids allowed)~* Child has a bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection (thrombocytopenia, coagulation disorder, anti-coagulant therapy)~* Child is or will be enrolled in any other clinical trial of a drug, vaccine or medical device during the study period~* Child is scheduled to receive a live vaccine (notably measles, mumps, rubella or varicella vaccines) during the study period~* Child has a health condition which, in the opinion of the investigator, would interfere with the evaluation or pose a health risk to the child

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 2 doses 0.5mL VAXIGRIP® at months 0, 1
- 2 (Type: ACTIVE_COMPARATOR): 2 doses 0.25mL VAXIGRIP® at months 0, 1

Based on this trial design, predict the completion outcome and termination type (if applicable).